Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
Latest News
Bioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsJun. 16, 2022
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting...
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&AJun. 14, 2022
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™...
Bioasis and Neuramedy Enter into Research Collaboration and License AgreementMay. 10, 2022
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary...